Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Melissa Tordoff"'
Autor:
Stephanie J.W. Shoop-Worrall, Saskia Lawson-Tovey, Lucy R. Wedderburn, Kimme L. Hyrich, Nophar Geifman, Aline Kimonyo, Alyssia McNeece, Andrew Dick, Andrew Morris, Annie Yarwood, Athimalaipet Ramanan, Bethany R. Jebson, Chris Wallace, Daniela Dastros-Pitei, Damian Tarasek, Elizabeth Ralph, Emil Carlsson, Emily Robinson, Emma Sumner, Fatema Merali, Fatjon Dekaj, Helen Neale, Hussein Al-Mossawi, Jacqui Roberts, Jenna F. Gritzfeld, Joanna Fairlie, John Bowes, John Ioannou, Melissa Kartawinata, Melissa Tordoff, Michael Barnes, Michael W. Beresford, Michael Stadler, Paul Martin, Rami Kallala, Sandra Ng, Samantha Smith, Sarah Clarke, Soumya Raychaudhuri, Stephen Eyre, Sumanta Mukherjee, Teresa Duerr, Thierry Sornasse, Vasiliki Alexiou, Victoria J. Burton, Wei-Yu Lin, Wendy Thomson, Zoe Wanstall
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104946- (2024)
Summary: Background: Methotrexate (MTX) is the gold-standard first-line disease-modifying anti-rheumatic drug for juvenile idiopathic arthritis (JIA), despite only being either effective or tolerated in half of children and young people (CYP). To fac
Externí odkaz:
https://doaj.org/article/c923074c829f4905a534120f1e8c1050
Autor:
Melissa Tordoff, Samantha Smith, Gillian Rice, Lucy Wedderburn, Kimme Hyrich, Andrew Morris, Tracy Briggs, Wendy Thomson, Stephen Eyre, John Bowes
Publikováno v:
Rheumatology Advances in Practice. 6
Introduction/Background Juvenile idiopathic arthritis (JIA) encompasses a group of heterogeneous rheumatic diseases of childhood onset. JIA can result in long term disability and remission is the main goal of treatment. However refractory disease can
Autor:
Annie, Yarwood, Stephanie, Shoop-Worrall, Elena, López-Isac, Samantha Louise, Smith, Andrew P, Morris, John David, Bowes, Melissa, Tordoff, Kimme L, Hyrich, Wendy, Thomson
Publikováno v:
Childhood Arthritis Prospective Study (CAPS) Group 2022, ' No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA ', Rheumatology (Oxford, England) . https://doi.org/10.1093/rheumatology/keab942
Objectives. The clinical progression of JIA is unpredictable. Knowing who will develop severe disease could facilitate rapid intensification of therapies. We use genetic variants conferring susceptibility to JIA to predict disease outcome measures. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::888138fb981f6768f49c5ac1c2c3103d
https://pure.manchester.ac.uk/ws/files/222263108/outcome_predictors_paper_2021_revision.docx
https://pure.manchester.ac.uk/ws/files/222263108/outcome_predictors_paper_2021_revision.docx